These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9413160)

  • 1. 5q-: does longer survival of female patients explain the preponderance.
    Pedersen B
    Anticancer Res; 1997; 17(5A):3281-5. PubMed ID: 9413160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anatomy of the 5q- deletion: different sex ratios and deleted 5q bands in MDS and AML.
    Pedersen B
    Leukemia; 1996 Dec; 10(12):1883-90. PubMed ID: 8946926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
    Lessard M; Hélias C; Struski S; Perrusson N; Uettwiller F; Mozziconacci MJ; Lafage-Pochitaloff M; Dastugue N; Terré C; Brizard F; Cornillet-Lefebvre P; Mugneret F; Barin C; Herry A; Luquet I; Desangles F; Michaux L; Verellen-Dumoulin C; Perrot C; Van den Akker J; Lespinasse J; Eclache V; Berger R;
    Cancer Genet Cytogenet; 2007 Jul; 176(1):1-21. PubMed ID: 17574959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and tricentric chromosomes, resulting in the loss of critical 5q regions.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; Morice P; Abgrall JF; Berthou C; De Braekeleer M
    Cancer Genet Cytogenet; 2007 Jun; 175(2):125-31. PubMed ID: 17556068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
    Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; De Braekeleer M
    Eur J Haematol; 2007 Jun; 78(6):457-67. PubMed ID: 17391336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetic analysis in patients with myelodysplastic syndrome.
    Hu N; Bian M
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(3):135-9. PubMed ID: 2098765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Submicroscopic deletions in 5q- associated malignancies.
    Crescenzi B; La Starza R; Romoli S; Beacci D; Matteucci C; Barba G; Aventin A; Marynen P; Ciolli S; Nozzoli C; Martelli MF; Mecucci C
    Haematologica; 2004 Mar; 89(3):281-5. PubMed ID: 15020265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5q-: pathogenetic importance of the common deleted region and clinical consequences of the entire deleted segment.
    Pedersen B
    Anticancer Res; 1993; 13(5C):1913-6. PubMed ID: 8267400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
    van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
    Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
    Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
    Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities.
    Estey EH; Pierce S; Keating MJ
    Haematologica; 2000 Mar; 85(3):246-9. PubMed ID: 10702811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic analysis of de novo acute myeloid leukemia with trilineage myelodysplasia in comparison with myelodysplastic syndrome evolving to acute myeloid leukemia.
    Tamura S; Takemoto Y; Hashimoto-Tamaoki T; Mimura K; Sugahara Y; Senoh J; Furuyama JI; Kakishita E
    Int J Oncol; 1998 Jun; 12(6):1259-62. PubMed ID: 9592183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10).
    Hsiao HH; Sashida G; Ito Y; Kodama A; Fukutake K; Ohyashiki JH; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Mar; 165(2):161-6. PubMed ID: 16527611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia.
    Trost D; Hildebrandt B; Beier M; Müller N; Germing U; Royer-Pokora B
    Cancer Genet Cytogenet; 2006 Feb; 165(1):51-63. PubMed ID: 16490597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.